Thursday, November 24, 2022 9:43:12 AM
November 24, 2022 09:18 ET
https://www.globenewswire.com/news-release/2022/11/24/2562285/0/en/Revive-Therapeutics-Announces-Update-for-Type-C-Meeting-to-Discuss-Amended-Protocol-Agreement-of-Phase-3-Clinical-Study-for-Bucillamine-in-the-Treatment-of-COVID-19.html
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM